Rantes, tnf→, oxidative stress, and hematological abnormalities in hepatitis c virus infection

Journal of Investigative Medicine

Volumn 60, Issue 6, 2012, Pages 878-882

  Tawadrous, Gamil Amin ^a   Aziz, Amal A ^a   Amin, Dalia G ^a   Eldemery, Ahmed ^a   Abdel Aziz, Mostafa ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b 6th of October City   (Egypt)

Author keywords

Chronic liver disease; Complete blood picture; MDA; Nitric oxide; RANTES; Real time PCR; TNF >

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN A1C; MALONALDEHYDE; NITRIC OXIDE; PROTHROMBIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; CCL5 PROTEIN, HUMAN;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASOPHIL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; ENZYME ACTIVITY; ERYTHROCYTE COUNT; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER CELL DAMAGE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPENIA; NEUTROPHIL COUNT; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; LIVER FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL5; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER FUNCTION TESTS; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 85047687733     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318254519e     Document Type: Article

References (40)

1. World Health Organization. Hepatitis C. Weekly epidemiological record. 1997;72:65-69.
2. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(suppl 1):9-16.
3. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000;132: 296-305.
4. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593-620.
5. Loetscher P, Seitz M, Clark-Lewis I, et al. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol. 1996;156:322-327.
6. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669-671.
7. Rot A, Krieger M, Brunner T, et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992;76:1489-1495.
8. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373-386.
9. Crispe IN, Dao T, Klugewitz K, et al. The liver as a site of T-cell apoptosis: graveyard, or killing field. Immunol Rev. 2000;174:47-62.
10. Soo HM, Garzino-Demo A, Hong W. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology. 2002;303:253-277.
11. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42(12):2487-2494.
12. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis. 2001;21(1):57-69.
13. Majano PL, Garcia-Monzon C. Does nitric oxide play a pathogenic role in hepatitis C virus infection? Cell Death Differ. 2003;10(suppl 1):S13YS15.
14. Mihm S, Fayyazi A, Ramadori G. Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology. 1997;26(2):451-458.
15. Streiff MB, Mehta S, Thoma DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology. 2002;35:947-952.
16. Abraham EC, Huff TA, Cope TA. Determination of HbA1c with a new microcolumn procedure. Diabetes. 1978;27:931-937.
17. Rizzetto M, Canese M, Avic S. Immunofluorescence detection of a new antigen-antibody system associated with hepatitis B virus in liver and serum of HBsAg carrier. Gut. 1977;18:997-1003.
18. Alter Robert H, Purcell James W, Shin P, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non A, non B hepatitis. N Engl J Med. 1989;321(22):1494-1500.
19. Sticherling M, Küpper M, Koltrowitz F, et al. Detection of the chemokine RANTES in stimulated human dermal fibroblasts. J Invest Dermatol. 1995;105:585-591.
20. Cannon TG, Nerd JL, Poutsikad DD, et al. Measuring circulating cytokines. J Appl Physiol. 1993;75:1897-1902.
21. Heydtmann M, Lalor PF, Eksteen JA, et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol. 2005;174:1055-1062.
22. Florholmen J, Kristiansen MG, Steigen SE, et al. A rapid chemokine response of macrophage inflammatory protein (MIP)-1>, MIP-1A and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. Clin Microbiol Infect. 2011;17(2):204-209.
23. Li K, Li NL, Wei D, et al. Activation of chemokine and inflammatory cytokine response in HCV-infected hepatocytes depends on TLR3 sensing of HCV dsRNA intermediates. Hepatology. 2012;55:666-675.
24. Kaser TH, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006;26:1029-1039.
25. Elsammak M, Refai W, Elsawaf A, et al. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin. 2005;21(4):527-533.
26. Talaat RM. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol. 2010;23(2):151-157.
27. Hung CH, Lee CM, Lu SN. Hepatitis C virusYassociated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011;9(5):525-333.
28. Parvaiz F, Manzoor S, Tariq H, et al. Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J. 2011;8(1):474.
29. Yoneda S, Umemura T, Joshita S, et al. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2011;41(6): 587-593.
30. Hirano F, Komura K, Fukawa E, et al. Tumor necrosis factor-> (TNF->)-induced RANTES chemokine expression via activation of NF-kappa B and p38 MAP kinase: roles of TNF-alpha in alcoholic liver diseases. J Hepatol. 2003;38(4):483-489 31.
31. Choi J, Lee KJ, Zheng Y, et al. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology. 2004;39(1):81-89.
32. Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med. 2000;6(5):347-373.
33. Ali EM, Shehata HH, Ali-Labib R, et al. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Clin Biochem. 2009;42(13-14):1394-1400.
34. Nakhjavani M, Mashayekh A, Khalilzadeh O, et al. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35(2):111-116.
35. Ozenirler S, Erkan G, Gulbahar O, et al. Serum levels of advanced oxidation protein products, MDA, and total radical trapping antioxidant parameter in patients with chronic hepatitis C. Turk J Gastroenterol. 2011;22(1):47-53.
36. Ijaz B, Ahmad W, Javed FT, et al. Association of laboratory parameters with viral factors in patients with hepatitis C. Virology J. 2011;8: 361-369.
37. Louie KS, Micallef JM, Pimenta JM, et al. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011;18(1):1-7.
38. Alvarez GC, Gomez-Galicia D, Rodriguez-Fragoso L, et al. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann Hepatol. 2011;10(4):458-468.
39. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol. 2006;78(4):459-465.
40. Martinez-Camacho A, Khaoustov VI, Adam E, et al. Lymphocytosis as a predictor of poor response to treatment of hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35(1):34-40.